ADIAL PHARMACEUTICALS, INC.
ADIAL PHARMACEUTICALS, INC. (ADIL): 1 pipeline candidate · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.7 months
D/E 0.41 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for ADIAL PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.9M
Cash
$4.6M
Quarterly Burn
$1.6M
Runway
8.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| AD04 | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$61K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 24,249 | $43K |
| vanguard fiduciary trust co | 5,879 | $11K |
| manchester capital management llc | 1,923 | $3K |
| blackrock, inc. | 1,110 | $2K |
| vanguard capital management llc | 722 | $1K |
| morgan stanley | 50 | $90 |
| wells fargo & company/mn | 6 | $11 |
| northwestern mutual wealth management co | 4 | $7 |
| harbour investments, inc. | 3 | $5 |
| abound wealth management | 1 | $2 |
Frequently asked questions
How many drug candidates are in ADIAL PHARMACEUTICALS, INC.'s pipeline?
ADIAL PHARMACEUTICALS, INC. (ADIL) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is ADIAL PHARMACEUTICALS, INC.'s lead drug candidate?
ADIAL PHARMACEUTICALS, INC.'s most advanced tracked candidate is AD04 (Phase 3) for Alcohol use disorder (AUD).
What is ADIAL PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ADIAL PHARMACEUTICALS, INC. has approximately 8.7 months of cash runway.
What is ADIAL PHARMACEUTICALS, INC.'s market capitalization?
ADIAL PHARMACEUTICALS, INC.'s market capitalization is approximately $5.9M.
Who is the CEO of ADIAL PHARMACEUTICALS, INC.?
Mr. Cary John Claiborne MBA is the chief executive officer of ADIAL PHARMACEUTICALS, INC. (ADIL).
Get the full picture on ADIAL PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.